The tubulin polymerization and Src kinase signaling inhibitor tirbanibulin is being investigated as a topical treatment for actinic keratosis, a precursor of squa- mous-cell carcinoma.
A total of 702 patients were enrolled in the two trials (351 patients per trial). Complete clearance in trial 1 occurred in 44% of the patients (77 of 175) in the tirbanibulin group and in 5% of those (8 of 176) in the vehicle group (difference, 40 percentage points; 95% confidence interval [CI], 32 to 47; P<0.001); in trial 2, the percentages were 54% (97 of 178 patients) and 13% (22 of 173), respectively (difference, 42 percentage points; 95% CI, 33 to 51; P<0.001). The percentages of patients with partial clearance were significantly higher in the tirbanibulin groups than in the vehicle groups. At 1 year, the estimated percentage of patients with recurrent lesions was 47% among patients who had had a complete response to tirbanibulin. The most common local reactions to tirbanibulin were erythema in 91% of the patients and flaking or scaling in 82%. Adverse events with tirbanibulin were application-site pain in 10% of the patients and pruritus in 9%, all of which resolved.
N Engl J Med 2021;384:512-20.
PRIME Time in Rheumatoid Arthritis
Identification of preinflammatory mesenchymal, or PRIME, cells — that appeared in blood just before disease flares, by sequential RNA analysis before and during flares of RA
Roflumilast Cream for Chronic Plaque Psoriasis
Roflumilast cream contains a PDE-4 inhibitor
The mean baseline PASI scores were 7.7 in the roflumilast 0.3% group, 8.0 in the roflumilast 0.15% group, and 7.6 in the vehicle group; the mean change from baseline at week 6 was −50.0%, −49.0%, and −17.8%
Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus
Nemolizumab is a subcutaneously administered humanized monoclonal antibody against interleukin-31 receptor A
The median VAS score (0-to-100 scale when the baseline score is 100)
for pruritus at baseline was 75. At week 16, the mean percent change in the VAS score was −42.8% in the nemolizumab group and −21.4% in the placebo group
The mean percent change in the EASI (0-72) score was −45.9% with nemolizumab and −33.2% with placebo.
DLQI score of 4 or less was 40% in the nemolizumab group and 22% in the placebo group
DLQI; (range, 0 to 30, with higher scores indicating a greater effect on daily life)
Kawasaki like Syndrome – „pediatric inflammatory multisystem syndrome“ or PIMS or „multisystem inflammatory syndrome in children“ or MIS-C. Skin or mucous membranes were involved in up to 87% of the children
Es handelt sich um ein Symptom des Cowden Syndroms:
Genetic testing was performed and showed an inactivating mutation in the tumor-suppressor gene encoding phosphatase and tensin homologue (PTEN). The Cowden syndrome, an autosomal dominant PTEN hamartoma syndrome, is associated with an increased risk of breast, thyroid, endometrial, and other cancers. Oral mucosal papillomas are commonly associated skin lesions. Adapted from N Engl J Med 2020; 382:e29